12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Erivedge vismodegib: Phase Ib data

Data from 34 patients with advanced sarcomas in the Phase Ib portion of an open-label, U.S. Phase Ib/II trial showed that once-daily 150 mg oral vismodegib plus once-daily 10 and 15 mg RO4929097 was well tolerated with no dose-limiting toxicities (DLTs) reported. Systemic exposure (peak plasma concentration and area under the curve (AUC) over 0-24 hours) of RO4929097 was about 70% lower in patients who received vismodegib plus RO4929097...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >